Company Name: AbbVie Inc.
Ticker: ABBV
Exchange: NYSE
SEC Filings (CIK): 0001551152
Investor Relations (IR) Website: https://investors.abbvie.com
Sector: Healthcare
Industry: Biotechnology / Pharmaceuticals
Business Overview
AbbVie Inc. is a global, research-driven biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative therapies. The company targets diseases with significant unmet medical needs, emphasizing long-term treatment franchises supported by scientific expertise, regulatory barriers, and intellectual property protection.
AbbVie’s portfolio spans immunology, oncology, neuroscience, aesthetics, and eye care, providing revenue diversification across therapeutic areas and reducing dependence on any single product. The company combines in-house R&D with targeted acquisitions to sustain pipeline depth and extend its product lifecycle strategy beyond patent expirations.
With a strong emphasis on biologics, specialty drugs, and first-in-class or best-in-class therapies, AbbVie benefits from high switching costs, complex manufacturing requirements, and durable pricing power typical of branded pharmaceuticals.
Key Brands / Products
Immunology
- Humira
- Skyrizi
- Rinvoq
Oncology
- Imbruvica
- Venclexta / Venclyxto
- Epkinly
- Elahere
Aesthetics
- Botox Cosmetic
- Juvederm Collection of Fillers
Neuroscience
- Botox Therapeutic
- Vraylar
- Duopa / Duodopa
- Ubrelvy
- Qulipta
Eye Care
- Ozurdex
- Lumigan / Ganfort
- Alphagan / Combigan
- Restasis
Other Key Products
- Mavyret / Maviret
- Creon
- Lupron
- Linzess / Constella
- Synthroid
Pipeline Highlights
- NX-13 – First-in-class oral NLRX1 agonist for ulcerative colitis and Crohn’s disease
- CEL383 – First-in-class anti-TREM1 antibody for inflammatory bowel disease
This page presents the Company Intelligence profile for AbbVie Inc., a constituent of the Million Leaf Investment Universe. It reflects our current assessment of the company’s business quality, competitive positioning, financial resilience, valuation framework compatibility, and risk landscape.
The content is maintained as a living intelligence record and is updated as new, decision-relevant information becomes available.
Million Leaf 